Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 334 for prevention of chronic migraine: Phase 2 randomized, double-blind, placebo-controlled trial
2013-001707-36Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic migraine and migraine comparing AMG 334 with Placebo (2 arms). Primary endpoint: Change in monthly migraine days. Started Nov 2013; status: completed.
02
Drugs
erenumab
03
Conditions
chronic migrainemigraine
Beyond the preview
Go deeper on 2013-001707-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001707-36.